Grifols (GRFS) Other Non-Current Assets (2009 - 2025)
Grifols' (GRFS) quarterly Other Non-Current Assets came in at $27.9 million in Q4 2025, down 31.2% YoY from $40.6 million in Q4 2024, and down 31.2% on a QoQ basis from $40.6 million in Q4 2024.
Grifols (GRFS) Other Non-Current Assets (2009 - 2025) Analysis & Trends
Grifols (GRFS) has 17 years of Other Non-Current Assets data on file, last reported at $27.9 million in Q4 2025.
- Quarterly Other Non-Current Assets fell 31.2% year-over-year to $27.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $27.9 million (down 31.2% YoY) and the FY2025 annual result came in at $27.9 million, down 31.2% from the prior year.
- Other Non-Current Assets fell to $27.9 million in Q4 2025, from $40.6 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $298.9 million in Q4 2021 to a low of $27.9 million in Q4 2025.
- A 5-year average of $128.0 million and a median of $126.7 million in 2022 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2021 — Other Non-Current Assets soared 132.07% — and 2024, when it slumped 72.17%.
- Tracing GRFS's Other Non-Current Assets over 5 years: stood at $298.9 million in 2021, then plunged by 57.61% to $126.7 million in 2022, then gained by 15.17% to $145.9 million in 2023, then tumbled by 72.17% to $40.6 million in 2024, then sank by 31.2% to $27.9 million in 2025.
- The last three Other Non-Current Assets figures came in at $27.9 million (Q4 2025), $40.6 million (Q4 2024), and $145.9 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 14.27 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 10.73 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 19.60 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.93 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 12.98 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 4.75 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 9.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 3.56 Bn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 27.94 Mn |
| Dec 31, 2024 | 40.61 Mn |
| Dec 31, 2023 | 145.93 Mn |
| Dec 31, 2022 | 126.71 Mn |
| Dec 31, 2021 | 298.91 Mn |
| Dec 31, 2020 | 128.80 Mn |
| Sep 30, 2020 | 147.64 Mn |
| Mar 31, 2020 | 145.22 Mn |
| Dec 31, 2019 | -15.35 Mn |
| Sep 30, 2019 | 133.28 Mn |
| Mar 31, 2019 | 137.44 Mn |
| Dec 31, 2018 | 2.18 Mn |
| Sep 30, 2018 | 78.26 Mn |
| Jun 30, 2018 | 10.24 Mn |
| Mar 31, 2018 | 75.04 Mn |
| Dec 31, 2017 | 77.90 Mn |
| Jun 30, 2017 | 46.41 Mn |
| Dec 31, 2016 | 1.16 Mn |
| Sep 30, 2016 | -723,287.54 |
| Jun 30, 2016 | 5.24 Mn |